DIACEUTICS PLC

Share Issue/Capital Change • Jun 11, 2020

National Storage Mechanism | Additional information

RNS Number : 7110P

Diaceutics PLC

11 June 2020

11 June 2020

Diaceutics PLC

("Diaceutics", the "Company" or the "Group")

Exercise of Warrant

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it has received notification for the exercise of a warrant over 347,915 ordinary shares in the Company at an exercise price of 76 pence per share providing the Company with proceeds of £264,415 ("Warrant Exercise").

Application has been made to the London Stock Exchange to admit the 347,915 new ordinary shares resulting from the Warrant Exercise to trading on AIM ("Admission"), which is expected to occur on 16 June 2020.  The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above and including the 10,437,000 Firm Placing shares to be issued in connection with the Firm Placing announced yesterday by the Company, on 16 June 2020 the Company's issued share capital admitted to trading on AIM will comprise 80,367,992 ordinary shares of 0.2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.  

Enquiries Diaceutics PLC
Stuart Hunt, Head of Investor Relations	Tel: +44 (0)7815 778 536
Cenkos Securities PLC (Nomad & Broker)	Tel: +44(0)20 7397 8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy	Tel: +44 (0)7876 741 001
Paul McManus	Tel: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is a diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOESFIFEFESSEIM